GILD’s Resurgence Could Result in Additional 30% Profits

by Sam Collins | May 14, 2014 1:06 am

Gilead Sciences (GILD[1]) — This has been a favorite biotech stock of mine since November 2012[2], when I recommended it near $37.50. I have covered it numerous times since then, most recently on April 15[3].

On April 22, the company reported non-GAAP diluted EPS of $1.48 per share versus a consensus estimate of $0.91. The next day, S&P reiterated its “strong buy” rating, raising it price target to $130 from $116. It cited continued robust sales of Gilead’s hepatitis C treatment, Sovaldi, and HIV treatment Stribild.

GILD was the victim of profit-taking in the biotech sector and pressure from the government to lower the price of Sovaldi. S&P analysts said they believe Gilead will make “some pricing concessions” for Medicaid patients.

The stock completed a bullish “V” bottom. Resistance remains at GILD’s old high at just under $85, but once this is exceeded our target is $105.

GILD Chart
Click to Enlarge

Chart Key[4]

  1. GILD:
  2. since November 2012:
  3. on April 15:
  4. [Image]:

Source URL:
Short URL: